rs587781653
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000051.4(ATM):c.4373delG(p.Gly1458GlufsTer15) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000411 in 1,461,452 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000051.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.4373delG | p.Gly1458GlufsTer15 | frameshift_variant | Exon 29 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251220Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135792
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1461452Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727024
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:5
- -
This sequence change in ATM is a frameshift variant predicted to cause a premature stop codon, p.(Gly1458Glufs*15), in biologically relevant exon 29/63 leading to nonsense-mediated decay in a gene in which loss-of-function is an established disease mechanism. This variant is present in a single individual from the European (non-Finnish) population in the population database gnomAD v2.1 (1/113,616 alleles). This variant has been reported in one individual with prostate cancer and a patient referred for cancer panel testing (PMID: 26681312, 32694154). This variant has been detected compound heterozygous with a second variant in at least three individuals with a clinical diagnosis of ataxia telangiectasia (PMID: 10330348, 18321536, 22649200). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as PATHOGENIC. Following criteria are met: PVS1, PM3_Strong, PM2_Supporting. -
This sequence change creates a premature translational stop signal (p.Gly1458Glufs*15) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is present in population databases (rs587781653, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with prostate cancer and ataxia-telangiectasia (PMID: 10330348, 22649200, 27433846). ClinVar contains an entry for this variant (Variation ID: 141315). For these reasons, this variant has been classified as Pathogenic. -
Variant summary: ATM c.4373delG (p.Gly1458GlufsX15) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 251220 control chromosomes. c.4373delG has been reported in the literature in individual(s) affected with Ataxia-Telangiectasia (e.g. Carney_2012). The following publication has been ascertained in the context of this evaluation (PMID: 22649200). ClinVar contains an entry for this variant (Variation ID: 141315). Based on the evidence outlined above, the variant was classified as pathogenic. -
ACMG codes:PVS1, PM2, PP5 -
Familial cancer of breast Pathogenic:3
The c.4373delG frame shift variant is predicted to yield loss of function transcripts/proteins of ATM gene, which is one of mechanisms causing Ataxia-telangiectasia. This variant is extremely rare in general population (1 in 246014 by gnomad) and observed in multiple ataxia-telangiectasia patients (PMID:10330348, 22649200). It has been also observed in other clinical labs and reported as a pathogenic. Based on the above evidences, we interpret this variant as pathogenic. -
- -
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
not provided Pathogenic:2
The ATM p.Gly1458Glufs*15 variant was identified in 5 of 7742 proband chromosomes (frequency: 0.0005) from individuals or families with Ataxia-telangiectasia, prostate cancer, and pancreatic cancer (Carney 2012, Li 2000, Pritchard 2016, Teraoka 1999, Hu 2018). The variant was also identified in dbSNP (ID: rs587781653) as “With Pathogenic allele”, ClinVar (as pathogenic by Ambry Genetics, GeneDx, and Invitae), Clinvitae (3x), and the ATM-LOVD (2x). The variant was not identified in Cosmic or MutDB databases. The variant was identified in control databases in 1 of 246014 chromosomes at a frequency of 0.000004 (Genome Aggregation Database Feb 27, 2017). The variant was identified in the European (Non-Finnish) population in 1 of 111568 chromosomes (freq: 0.000009), but not in the African, Ashkenazi Jewish, East Asian, Finnish, Latino, Other, and South Asian populations. The p.Gly1458Glufs*15 variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 1458 and leads to a premature stop codon at position 1472. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the ATM gene are an established mechanism of disease in ATM-associated Cancer and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek 2016); This variant is associated with the following publications: (PMID: 26681312, 10330348, 10817650, 22649200, 27433846, 31447099, 31948886) -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.4373delG pathogenic mutation, located in coding exon 28 of the ATM gene, results from a deletion of one nucleotide at nucleotide position 4373, causing a translational frameshift with a predicted alternate stop codon (p.G1458Efs*15). This mutation has been reported in several patients with classic ataxia-telangiectasia (Teraoka SN et al. Am. J. Hum. Genet. 1999; 64:1617-31, Li A et al. Am J Med Genet. 2000 May 29;92(3):170-7; Du L et al. Mutat Res, 2008 Apr;640:139-44; Carney EF et al. J Immunol, 2012 Jul;189:261-8). This mutation was also detected in men diagnosed with prostate cancer (Pritchard CC et al. N. Engl. J. Med., 2016 Aug;375:443-53; Wu Y et al. Eur Urol Oncol, 2020 04;3:224-230). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant deletes 1 nucleotide in exon 29 of the ATM gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been observed in multiple individuals affected with ataxia telangiectasia including compound heterozygous and homozygous carriers (PMID: 10330348, 10817650, 22649200). This variant has been identified in 1/251220 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at